Advertisement

Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics

Published:November 13, 2018DOI:https://doi.org/10.1016/j.metabol.2018.11.002

      Highlights

      • Characteristics of obesity in PCOS: etiology, treatment, and genetics
      • Obesity, common, often visceral, not necessary nor sufficient for PCOS development
      • PCOS is a complex polygenic trait, with marked familial clustering.
      • Lifestyle interventions targeted to ≥5% weight loss have major metabolic benefit.
      • Pharmacologic therapy often required; bariatric surgery an important option

      Abstract

      Polycystic ovary syndrome (PCOS) has multiple etiologies including ovarian and adrenal hyperandrogenism, neuro-endocrine and hypothalamic-pituitary dysfunction, and disorders of peripheral insulin resistance. Obesity is neither necessary nor sufficient for the PCOS phenotype, and the association of PCOS with obesity is not universal, with national, cultural, and ethnic differences. Obesity, particularly visceral adiposity which is common in obese and non-obese women with PCOS, amplifies and worsens all metabolic and reproductive outcomes in PCOS. Obesity increases insulin resistance and compensatory hyperinsulinemia, which in turn increases adipogenesis and decreases lipolysis. Obesity sensitizes thecal cells to LH stimulation and amplifies functional ovarian hyperandrogenism by upregulating ovarian androgen production. Obesity increases inflammatory adipokines which, in turn, increase insulin resistance and adipogenesis. Lifestyle interventions focused on diet-weight loss and concurrent exercise are central to therapy which also commonly subsequently needs to include pharmacologic therapy. PCOS symptoms commonly improve with 5% to 10% weight loss, but 25% to 50% weight loss, usually achievable only through bariatric surgery, may be required for morbid obesity unresponsive to lifestyle-medical treatment. Bariatric surgery is a valuable approach to weight loss in PCOS where BMI is ≥40 kg/m2 when non-surgical treatment and/or induction of pregnancy have failed, and can be an initial treatment when BMI is ≥50 kg/m2. Further research in PCOS is needed to better understand the fundamental basis of the disorder, to ameliorate obesity, to correct hyperandrogenism, ovulation, hyperinsulinemia, and to optimize metabolic homeostasis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Azziz R.
        • Woods K.S.
        • Reyna R.
        • Key T.J.
        • Knochenhauer E.S.
        • Yildiz B.O.
        The prevalence and features of the polycystic ovary syndrome in an unselected population.
        J Clin Endocrinol Metab. 2004; 89: 2745-2749
        • Bozdag G.
        • Mumusoglu S.
        • Zengin D.
        • Karabulut E.
        • Yildiz B.O.
        The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod. 2016; 31: 2841-2855
        • Hoeger K.M.
        Obesity and lifestyle management in polycystic ovary syndrome.
        Clin Obstet Gynecol. 2007; 50: 277-294
        • Ding T.
        • Hardiman P.J.
        • Petersen I.
        • Wang F.F.
        • Qu F.
        • Baio G.
        The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis.
        Oncotarget. 2017; 8: 96351-96358
        • Durmus U.
        • Duran C.
        • Ecirli S.
        Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
        J Endocrinol Invest. 2017; 40: 487-497
        • Glueck C.J.
        • Dharashivkar S.
        • Wang P.
        • Zhu B.
        • Gartside P.S.
        • Tracy T.
        • et al.
        Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy.
        Eur J Obstet Gynecol Reprod Biol. 2005; 122: 206-212
        • Norman R.J.
        • Masters L.
        • Milner C.R.
        • Wang J.X.
        • Davies M.J.
        Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.
        Hum Reprod. 2001; 16: 1995-1998
        • Legro R.S.
        Obesity and PCOS: implications for diagnosis and treatment.
        Semin Reprod Med. 2012; 30: 496-506
        • Baillargeon J.P.
        • Nestler J.E.
        Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?.
        J Clin Endocrinol Metab. 2006; 91: 22-24
        • Glueck C.J.
        • Goldenberg N.
        • Pranikoff J.
        • Khan Z.
        • Padda J.
        • Wang P.
        Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome.
        Curr Med Res Opin. 2013; 29: 55-62
        • Zeng X.L.
        • Zhang Y.F.
        • Tian Q.
        • Xue Y.
        • An R.F.
        Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis.
        Medicine (Baltimore). 2016; 95: e4526
        • Samuel V.T.
        • Petersen K.F.
        • Shulman G.I.
        Lipid-induced insulin resistance: unravelling the mechanism.
        Lancet. 2010; 375: 2267-2277
        • Jena D.
        • Choudhury A.K.
        • Mangaraj S.
        • Singh M.
        • Mohanty B.K.
        • Baliarsinha A.K.
        Study of visceral and subcutaneous abdominal fat thickness and its correlation with cardiometabolic risk factors and hormonal parameters in polycystic ovary syndrome.
        Indian J Endocrinol Metab. 2018; 22: 321-327
        • Rosenfield R.L.
        • Ehrmann D.A.
        The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited.
        Endocr Rev. 2016; 37: 467-520
        • Cascella T.
        • Palomba S.
        • De Sio I.
        • Manguso F.
        • Giallauria F.
        • De Simone B.
        • et al.
        Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome.
        Hum Reprod. 2008; 23: 153-159
        • Tripathy P.
        • Sahu A.
        • Sahu M.
        • Nagy A.
        Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome.
        Eur J Obstet Gynecol Reprod Biol. 2017; 217: 18-22
        • Melo A.S.
        • Vieira C.S.
        • Barbieri M.A.
        • Rosa E.S.A.C.
        • Silva A.A.
        • Cardoso V.C.
        • et al.
        High prevalence of polycystic ovary syndrome in women born small for gestational age.
        Hum Reprod. 2010; 25: 2124-2131
        • Ibanez L.
        • Potau N.
        • Francois I.
        • de Zegher F.
        Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.
        J Clin Endocrinol Metab. 1998; 83: 3558-3562
        • Mumm H.
        • Kamper-Jorgensen M.
        • Nybo Andersen A.M.
        • Glintborg D.
        • Andersen M.
        Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973–1991.
        Fertil Steril. 2013; 99: 777-782
        • Puttabyatappa M.
        • Cardoso R.C.
        • Padmanabhan V.
        Effect of maternal PCOS and PCOS-like phenotype on the offspring's health.
        Mol Cell Endocrinol. 2016; 435: 29-39
        • Sir-Petermann T.
        • Maliqueo M.
        • Angel B.
        • Lara H.E.
        • Perez-Bravo F.
        • Recabarren S.E.
        Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.
        Hum Reprod. 2002; 17: 2573-2579
        • Glueck C.J.
        • Morrison J.A.
        • Wang P.
        • Woo J.G.
        Early and late menarche are associated with oligomenorrhea and predict metabolic syndrome 26 years later.
        Metabolism. 2013; 62: 1597-1606
        • Glueck C.J.
        • Woo J.G.
        • Khoury P.R.
        • Morrison J.A.
        • Daniels S.R.
        • Wang P.
        Adolescent oligomenorrhea (age 14–19) tracks into the third decade of life (age 20–28) and predicts increased cardiovascular risk factors and metabolic syndrome.
        Metabolism. 2015; 64: 539-553
        • Boyle J.A.
        • Cunningham J.
        • Norman R.J.
        • Dunbar T.
        • O'Dea K.
        Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women.
        Intern Med J. 2015; 45: 1247-1254
        • Hu X.
        • Wang J.
        • Dong W.
        • Fang Q.
        • Hu L.
        • Liu C.
        A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy.
        Epilepsy Res. 2011; 97: 73-82
        • Doi S.A.
        Neuroendocrine dysfunction in PCOS: a critique of recent reviews.
        Clin Med Res. 2008; 6: 47-53
        • Anagnostis P.
        • Tarlatzis B.C.
        • Kauffman R.P.
        Polycystic ovarian syndrome (PCOS): long-term metabolic consequences.
        Metabolism. 2018; 86: 33-43
        • Goodman N.F.
        • Cobin R.H.
        • Futterweit W.
        • Glueck J.S.
        • Legro R.S.
        • Carmina E.
        • et al.
        American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2.
        Endocr Pract. 2015; 21: 1415-1426
        • Einarsson S.
        • Bergh C.
        • Friberg B.
        • Pinborg A.
        • Klajnbard A.
        • Karlstrom P.O.
        • et al.
        Weight reduction intervention for obese infertile women prior to IVF: a randomized controlled trial.
        Hum Reprod. 2017; 32: 1621-1630
        • Chaudhari N.
        • Dawalbhakta M.
        • Nampoothiri L.
        GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile.
        Reprod Biol Endocrinol. 2018; 16: 37
        • Moore A.M.
        • Campbell R.E.
        Polycystic ovary syndrome: understanding the role of the brain.
        Front Neuroendocrinol. 2017; 46: 1-14
        • Caldwell A.S.L.
        • Edwards M.C.
        • Desai R.
        • Jimenez M.
        • Gilchrist R.B.
        • Handelsman D.J.
        • et al.
        Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
        Proc Natl Acad Sci U S A. 2017; 114: E3334-E3343
        • Blank S.K.
        • McCartney C.R.
        • Helm K.D.
        • Marshall J.C.
        Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
        Semin Reprod Med. 2007; 25: 352-359
        • Blank S.K.
        • McCartney C.R.
        • Marshall J.C.
        The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome.
        Hum Reprod Update. 2006; 12: 351-361
        • James W.P.
        WHO recognition of the global obesity epidemic.
        Int J Obes (Lond). 2008; 32: S120-S126
        • Turkmen S.
        • Ahangari A.
        • Backstrom T.
        Roux-en-Y gastric bypass surgery in patients with polycystic ovary syndrome and metabolic syndrome.
        Obes Surg. 2016; 26: 111-118
        • Escobar-Morreale H.F.
        • Botella-Carretero J.I.
        • Alvarez-Blasco F.
        • Sancho J.
        • San Millan J.L.
        The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery.
        J Clin Endocrinol Metab. 2005; 90: 6364-6369
        • Rosen E.D.
        • Spiegelman B.M.
        What we talk about when we talk about fat.
        Cell. 2014; 156: 20-44
        • Gonzalez F.
        Nutrient-induced inflammation in polycystic ovary syndrome: role in the development of metabolic aberration and ovarian dysfunction.
        Semin Reprod Med. 2015; 33: 276-286
        • Roth L.W.
        • Allshouse A.A.
        • Bradshaw-Pierce E.L.
        • Lesh J.
        • Chosich J.
        • Kohrt W.
        • et al.
        Luteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight women.
        Clin Endocrinol (Oxf). 2014; 81: 418-425
        • Taponen S.
        • Martikainen H.
        • Jarvelin M.R.
        • Laitinen J.
        • Pouta A.
        • Hartikainen A.L.
        • et al.
        Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study.
        J Clin Endocrinol Metab. 2003; 88: 141-147
        • Cassar S.
        • Misso M.L.
        • Hopkins W.G.
        • Shaw C.S.
        • Teede H.J.
        • Stepto N.K.
        Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies.
        Hum Reprod. 2016; 31: 2619-2631
        • Lim S.S.
        • Norman R.J.
        • Davies M.J.
        • Moran L.J.
        The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis.
        Obes Rev. 2013; 14: 95-109
        • Glintborg D.
        • Rubin K.H.
        • Nybo M.
        • Abrahamsen B.
        • Andersen M.
        Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.
        Cardiovasc Diabetol. 2018; 17: 37
        • Solomon C.G.
        • Hu F.B.
        • Dunaif A.
        • Rich-Edwards J.E.
        • Stampfer M.J.
        • Willett W.C.
        • et al.
        Menstrual cycle irregularity and risk for future cardiovascular disease.
        J Clin Endocrinol Metab. 2002; 87: 2013-2017
        • Krentz A.J.
        • von Muhlen D.
        • Barrett-Connor E.
        Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease.
        Menopause. 2007; 14: 284-292
        • Legro R.S.
        • Driscoll D.
        • Strauss III, J.F.
        • Fox J.
        • Dunaif A.
        Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.
        Proc Natl Acad Sci U S A. 1998; 95: 14956-14960
        • Vink J.M.
        • Sadrzadeh S.
        • Lambalk C.B.
        • Boomsma D.I.
        Heritability of polycystic ovary syndrome in a Dutch twin-family study.
        J Clin Endocrinol Metab. 2006; 91: 2100-2104
        • Day F.R.
        • Hinds D.A.
        • Tung J.Y.
        • Stolk L.
        • Styrkarsdottir U.
        • Saxena R.
        • et al.
        Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome.
        Nat Commun. 2015; 6: 8464
        • Shi Y.
        • Zhao H.
        • Shi Y.
        • Cao Y.
        • Yang D.
        • Li Z.
        • et al.
        Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome.
        Nat Genet. 2012; 44: 1020-1025
        • Chen Z.J.
        • Zhao H.
        • He L.
        • Shi Y.
        • Qin Y.
        • Shi Y.
        • et al.
        Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.
        Nat Genet. 2011; 43: 55-59
        • Hayes M.G.
        • Urbanek M.
        • Ehrmann D.A.
        • Armstrong L.L.
        • Lee J.Y.
        • Sisk R.
        • et al.
        Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.
        Nat Commun. 2015; 6: 7502
        • Gao J.
        • Xue J.D.
        • Li Z.C.
        • Zhou L.
        • Chen C.
        The association of DENND1A gene polymorphisms and polycystic ovary syndrome risk: a systematic review and meta-analysis.
        Arch Gynecol Obstet. 2016; 294: 1073-1080
        • Liu A.L.
        • Xie H.J.
        • Xie H.Y.
        • Liu J.
        • Yin J.
        • Hu J.S.
        • et al.
        Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis.
        BMC Med Genet. 2017; 18: 89
        • Goodarzi M.O.
        • Jones M.R.
        • Li X.
        • Chua A.K.
        • Garcia O.A.
        • Chen Y.D.
        • et al.
        Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.
        J Med Genet. 2012; 49: 90-95
        • Welt C.K.
        • Styrkarsdottir U.
        • Ehrmann D.A.
        • Thorleifsson G.
        • Arason G.
        • Gudmundsson J.A.
        • et al.
        Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry.
        J Clin Endocrinol Metab. 2012; 97: E1342-E1347
        • Cui L.
        • Zhao H.
        • Zhang B.
        • Qu Z.
        • Liu J.
        • Liang X.
        • et al.
        Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women.
        Hum Reprod. 2013; 28: 538-544
        • Chen L.
        • Hu L.M.
        • Wang Y.F.
        • Yang H.Y.
        • Huang X.Y.
        • Zhou W.
        • et al.
        Genome-wide association study for SNPs associated with PCOS in human patients.
        Exp Ther Med. 2017; 14: 4896-4900
        • Dallel M.
        • Sarray S.
        • Douma Z.
        • Hachani F.
        • Al-Ansari A.K.
        • Letaifa D.B.
        • et al.
        Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women.
        Gene. 2018; 647: 79-84
        • Ding L.
        • Gao F.
        • Zhang M.
        • Yan W.
        • Tang R.
        • Zhang C.
        • et al.
        Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome.
        Fertil Steril. 2016; 105 ([e3]): 1330-1337
        • Hwang J.Y.
        • Lee E.J.
        • Jin Go M.
        • Sung Y.A.
        • Lee H.J.
        • Heon Kwak S.
        • et al.
        Genome-wide association study identifies GYS2 as a novel genetic factor for polycystic ovary syndrome through obesity-related condition.
        J Hum Genet. 2012; 57: 660-664
        • Barber T.M.
        • Bennett A.J.
        • Groves C.J.
        • Sovio U.
        • Ruokonen A.
        • Martikainen H.
        • et al.
        Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome.
        Diabetologia. 2008; 51: 1153-1158
        • Wojciechowski P.
        • Lipowska A.
        • Rys P.
        • Ewens K.G.
        • Franks S.
        • Tan S.
        • et al.
        Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis.
        Diabetologia. 2012; 55: 2636-2645
        • Teede H.J.
        • Misso M.L.
        • Costello M.F.
        • Dokras A.
        • Laven J.
        • Moran L.
        • et al.
        Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
        Hum Reprod. 2018; 86: 33-43
        • Teede H.
        • Deeks A.
        • Moran L.
        Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.
        BMC Med. 2010; 8: 41
        • Moran L.J.
        • Pasquali R.
        • Teede H.J.
        • Hoeger K.M.
        • Norman R.J.
        Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society.
        Fertil Steril. 2009; 92: 1966-1982
        • Crosignani P.G.
        • Colombo M.
        • Vegetti W.
        • Somigliana E.
        • Gessati A.
        • Ragni G.
        Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet.
        Hum Reprod. 2003; 18: 1928-1932
        • Moran L.J.
        • Brinkworth G.
        • Noakes M.
        • Norman R.J.
        Effects of lifestyle modification in polycystic ovarian syndrome.
        Reprod Biomed Online. 2006; 12: 569-578
        • Teede H.J.
        • Misso M.L.
        • Costello M.F.
        • Dokras A.
        • Laven J.
        • Moran L.
        • et al.
        Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
        Fertil Steril. 2018; 110: 364-379
        • Jamal M.
        • Gunay Y.
        • Capper A.
        • Eid A.
        • Heitshusen D.
        • Samuel I.
        Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis.
        Surg Obes Relat Dis. 2012; 8: 440-444
        • Guzick D.S.
        • Wing R.
        • Smith D.
        • Berga S.L.
        • Winters S.J.
        Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.
        Fertil Steril. 1994; 61: 598-604
        • Clark A.M.
        • Ledger W.
        • Galletly C.
        • Tomlinson L.
        • Blaney F.
        • Wang X.
        • et al.
        Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women.
        Hum Reprod. 1995; 10: 2705-2712
        • Holte J.
        • Bergh T.
        • Berne C.
        • Wide L.
        • Lithell H.
        Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 1995; 80: 2586-2593
        • Huber-Buchholz M.M.
        • Carey D.G.
        • Norman R.J.
        Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.
        J Clin Endocrinol Metab. 1999; 84: 1470-1474
        • Solomon C.G.
        • Dluhy R.G.
        Bariatric surgery—quick fix or long-term solution?.
        N Engl J Med. 2004; 351: 2751-2753
        • Norman R.J.
        • Davies M.J.
        • Lord J.
        • Moran L.J.
        The role of lifestyle modification in polycystic ovary syndrome.
        Trends Endocrinol Metab. 2002; 13: 251-257
        • Pasquali R.
        • Gambineri A.
        • Biscotti D.
        • Vicennati V.
        • Gagliardi L.
        • Colitta D.
        • et al.
        Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2000; 85: 2767-2774
        • Kiddy D.S.
        • Hamilton-Fairley D.
        • Bush A.
        • Short F.
        • Anyaoku V.
        • Reed M.J.
        • et al.
        Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.
        Clin Endocrinol (Oxf). 1992; 36: 105-111
        • Moran L.J.
        • Hutchison S.K.
        • Norman R.J.
        • Teede H.J.
        Lifestyle changes in women with polycystic ovary syndrome.
        Cochrane Database Syst Rev. 2011, Jul 6; 7CD007506
        • Kataoka J.
        • Tassone E.C.
        • Misso M.
        • Joham A.E.
        • Stener-Victorin E.
        • Teede H.
        • et al.
        Weight management interventions in women with and without PCOS: a systematic review.
        Nutrients. 2017; 9
        • Domecq J.P.
        • Prutsky G.
        • Mullan R.J.
        • Hazem A.
        • Sundaresh V.
        • Elamin M.B.
        • et al.
        Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.
        J Clin Endocrinol Metab. 2013; 98: 4655-4663
        • Pelletier L.
        • Baillargeon J.P.
        Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice.
        Fertil Steril. 2010; 94: 2665-2669
        • Tolino A.
        • Gambardella V.
        • Caccavale C.
        • D'Ettore A.
        • Giannotti F.
        • D'Anto V.
        • et al.
        Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome.
        Eur J Obstet Gynecol Reprod Biol. 2005; 119: 87-93
        • Guzick D.S.
        Polycystic ovary syndrome.
        Obstet Gynecol. 2004; 103: 181-193
        • Nikokavoura E.A.
        • Johnston K.L.
        • Broom J.
        • Wrieden W.L.
        • Rolland C.
        Weight loss for women with and without polycystic ovary syndrome following a very low-calorie diet in a community-based setting with trained facilitators for 12 weeks.
        Diabetes Metab Syndr Obes. 2015; 8: 495-503
        • Christ J.P.
        • Falcone T.
        Bariatric surgery improves hyperandrogenism, menstrual irregularities, and metabolic dysfunction among women with polycystic ovary syndrome (PCOS).
        Obes Surg. 2018; 28: 2171-2177
        • Abiad F.
        • Khalife D.
        • Safadi B.
        • Alami R.
        • Awwad J.
        • Khalifeh F.
        • et al.
        The effect of bariatric surgery on inflammatory markers in women with polycystic ovarian syndrome.
        Diabetes Metab Syndr. 2018; 12: 999-1005
        • Skubleny D.
        • Switzer N.J.
        • Gill R.S.
        • Dykstra M.
        • Shi X.
        • Sagle M.A.
        • et al.
        The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis.
        Obes Surg. 2016; 26: 169-176
        • Nilsson-Condori E.
        • Hedenbro J.L.
        • Thurin-Kjellberg A.
        • Giwercman A.
        • Friberg B.
        Impact of diet and bariatric surgery on anti-Mullerian hormone levels.
        Hum Reprod. 2018; 33: 690-693
        • Chiofalo F.
        • Ciuoli C.
        • Formichi C.
        • Selmi F.
        • Forleo R.
        • Neri O.
        • et al.
        Bariatric surgery reduces serum anti-mullerian hormone levels in obese women with and without polycystic ovarian syndrome.
        Obes Surg. 2017; 27: 1750-1754
        • Butterworth J.
        • Deguara J.
        • Borg C.M.
        Bariatric surgery, polycystic ovary syndrome, and infertility.
        J Obes. 2016; 2016: 1871594
        • Legro R.S.
        • Dodson W.C.
        • Kris-Etherton P.M.
        • Kunselman A.R.
        • Stetter C.M.
        • Williams N.I.
        • et al.
        Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2015; 100: 4048-4058
        • Legro R.S.
        • Dodson W.C.
        • Kunselman A.R.
        • Stetter C.M.
        • Kris-Etherton P.M.
        • Williams N.I.
        • et al.
        Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS.
        J Clin Endocrinol Metab. 2016; 101: 2658-2666
        • Palomba S.
        • Giallauria F.
        • Falbo A.
        • Russo T.
        • Oppedisano R.
        • Tolino A.
        • et al.
        Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study.
        Hum Reprod. 2008; 23: 642-650
        • Palomba S.
        • Falbo A.
        • Giallauria F.
        • Russo T.
        • Rocca M.
        • Tolino A.
        • et al.
        Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial.
        Hum Reprod. 2010; 25: 2783-2791
        • Moran L.J.
        • Noakes M.
        • Clifton P.M.
        • Wittert G.A.
        • Williams G.
        • Norman R.J.
        Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome.
        Am J Clin Nutr. 2006; 84: 77-87
        • Morley L.C.
        • Tang T.
        • Yasmin E.
        • Norman R.J.
        • Balen A.H.
        Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
        Cochrane Database Syst Rev. 2017; 11CD003053
        • Azadi-Yazdi M.
        • Karimi-Zarchi M.
        • Salehi-Abargouei A.
        • Fallahzadeh H.
        • Nadjarzadeh A.
        Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial.
        J Hum Nutr Diet. 2017; 30: 275-283
        • Mehrabani H.H.
        • Salehpour S.
        • Amiri Z.
        • Farahani S.J.
        • Meyer B.J.
        • Tahbaz F.
        Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study.
        J Am Coll Nutr. 2012; 31: 117-125
        • Moran L.J.
        • Noakes M.
        • Clifton P.M.
        • Tomlinson L.
        • Galletly C.
        • Norman R.J.
        Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2003; 88: 812-819
        • Marsh K.A.
        • Steinbeck K.S.
        • Atkinson F.S.
        • Petocz P.
        • Brand-Miller J.C.
        Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.
        Am J Clin Nutr. 2010; 92: 83-92
        • Hollmann M.
        • Runnebaum B.
        • Gerhard I.
        Effects of weight loss on the hormonal profile in obese, infertile women.
        Hum Reprod. 1996; 11: 1884-1891
        • Kuchenbecker W.K.
        • Groen H.
        • van Asselt S.J.
        • Bolster J.H.
        • Zwerver J.
        • Slart R.H.
        • et al.
        In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation.
        Hum Reprod. 2011; 26: 2505-2512
        • Vigorito C.
        • Giallauria F.
        • Palomba S.
        • Cascella T.
        • Manguso F.
        • Lucci R.
        • et al.
        Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2007; 92: 1379-1384
        • Bruner B.
        • Chad K.
        • Chizen D.
        Effects of exercise and nutritional counseling in women with polycystic ovary syndrome.
        Appl Physiol Nutr Metab. 2006; 31: 384-391
        • Thomson R.L.
        • Buckley J.D.
        • Lim S.S.
        • Noakes M.
        • Clifton P.M.
        • Norman R.J.
        • et al.
        Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome.
        Fertil Steril. 2010; 94: 1812-1816
        • Redman L.M.
        • Elkind-Hirsch K.
        • Ravussin E.
        Aerobic exercise in women with polycystic ovary syndrome improves ovarian morphology independent of changes in body composition.
        Fertil Steril. 2011; 95: 2696-2699
        • Bates G.W.
        • Legro R.S.
        Longterm management of Polycystic Ovarian Syndrome (PCOS).
        Mol Cell Endocrinol. 2013; 373: 91-97
        • Hall K.D.
        • Sacks G.
        • Chandramohan D.
        • Chow C.C.
        • Wang Y.C.
        • Gortmaker S.L.
        • et al.
        Quantification of the effect of energy imbalance on bodyweight.
        Lancet. 2011; 378: 826-837
        • Wang F.F.
        • Wu Y.
        • Zhu Y.H.
        • Ding T.
        • Batterham R.L.
        • Qu F.
        • et al.
        Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.
        Obes Rev. 2018; 19: 1424-1445
        • Florakis D.
        • Diamanti-Kandarakis E.
        • Katsikis I.
        • Nassis G.P.
        • Karkanaki A.
        • Georgopoulos N.
        • et al.
        Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
        Int J Obes (Lond). 2008; 32: 692-699
        • Lindholm A.
        • Bixo M.
        • Bjorn I.
        • Wolner-Hanssen P.
        • Eliasson M.
        • Larsson A.
        • et al.
        Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
        Fertil Steril. 2008; 89: 1221-1228
        • Jordan J.
        • Scholze J.
        • Matiba B.
        • Wirth A.
        • Hauner H.
        • Sharma A.M.
        Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
        Int J Obes (Lond). 2005; 29: 509-516
        • Naderpoor N.
        • Shorakae S.
        • de Courten B.
        • Misso M.L.
        • Moran L.J.
        • Teede H.J.
        Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
        Hum Reprod Update. 2015; 21: 560-574
        • Nieuwenhuis-Ruifrok A.E.
        • Kuchenbecker W.K.
        • Hoek A.
        • Middleton P.
        • Norman R.J.
        Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.
        Hum Reprod Update. 2009; 15: 57-68
        • Luque-Ramirez M.
        • Nattero-Chavez L.
        • Ortiz Flores A.E.
        • Escobar-Morreale H.F.
        Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod Update. 2017 Dec 27; https://doi.org/10.1093/humupd/dmx039
        • De Leo V.
        • la Marca A.
        • Petraglia F.
        Insulin-lowering agents in the management of polycystic ovary syndrome.
        Endocr Rev. 2003; 24: 633-667
        • Moghetti P.
        • Castello R.
        • Negri C.
        • Tosi F.
        • Perrone F.
        • Caputo M.
        • et al.
        Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
        J Clin Endocrinol Metab. 2000; 85: 139-146
        • Legro R.S.
        Evaluation and treatment of polycystic ovary syndrome.
        in: De Groot L.J. Chrousos G. Dungan K. Feingold K.R. Grossman A. Hershman J.M. Endotext. 2000 (South Dartmouth (MA))
        • Velazquez E.M.
        • Mendoza S.
        • Hamer T.
        • Sosa F.
        • Glueck C.J.
        Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
        Metabolism. 1994; 43: 647-654
        • Trolle B.
        • Flyvbjerg A.
        • Kesmodel U.
        • Lauszus F.F.
        Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
        Hum Reprod. 2007; 22: 2967-2973
        • Glueck C.J.
        • Aregawi D.
        • Agloria M.
        • Winiarska M.
        • Sieve L.
        • Wang P.
        Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
        Metabolism. 2006; 55: 1582-1589
        • Romualdi D.
        • Giuliani M.
        • Cristello F.
        • Fulghesu A.M.
        • Selvaggi L.
        • Lanzone A.
        • et al.
        Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.
        Fertil Steril. 2010; 93: 2303-2310
        • Velazquez E.M.
        • Mendoza S.G.
        • Wang P.
        • Glueck C.J.
        Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
        Metabolism. 1997; 46: 454-457
        • Burchall G.F.
        • Piva T.J.
        • Ranasinha S.
        • Teede H.J.
        Differential effects on haemostatic markers by metformin and the contraceptive pill: a randomized comparative trial in PCOS.
        Thromb Haemost. 2017; 117: 2053-2062
        • Jensterle M.
        • Pirs B.
        • Goricar K.
        • Dolzan V.
        • Janez A.
        Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
        Eur J Clin Pharmacol. 2015; 71: 817-824
        • Niafar M.
        • Pourafkari L.
        • Porhomayon J.
        • Nader N.
        A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
        Arch Gynecol Obstet. 2016; 293: 509-515
        • Frossing S.
        • Nylander M.
        • Chabanova E.
        • Frystyk J.
        • Holst J.J.
        • Kistorp C.
        • et al.
        Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial.
        Diabetes Obes Metab. 2018; 20: 215-218
        • Frossing S.
        • Nylander M.
        • Kistorp C.
        • Skouby S.O.
        • Faber J.
        Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS.
        Endocr Connect. 2018; 7: 115-123
        • Nylander M.
        • Frossing S.
        • Clausen H.V.
        • Kistorp C.
        • Faber J.
        • Skouby S.O.
        Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
        Reprod Biomed Online. 2017; 35: 121-127
        • Nylander M.
        • Frossing S.
        • Kistorp C.
        • Faber J.
        • Skouby S.O.
        Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.
        Endocr Connect. 2017; 6: 89-99
        • Lamos E.M.
        • Malek R.
        • Davis S.N.
        GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
        Expert Rev Clin Pharmacol. 2017; 10: 401-408
        • Jensterle M.
        • Kravos N.A.
        • Pfeifer M.
        • Kocjan T.
        • Janez A.
        A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
        Hormones (Athens). 2015; 14: 81-90
        • Jensterle M.
        • Goricar K.
        • Janez A.
        Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study.
        Exp Ther Med. 2016; 11: 1194-1200
        • Jensterle M.
        • Kravos N.A.
        • Goricar K.
        • Janez A.
        Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
        BMC Endocr Disord. 2017; 17: 5
        • Salamun V.
        • Jensterle M.
        • Janez A.
        • Vrtacnik Bokal E.
        Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
        Eur J Endocrinol. 2018; 179: 1-11
        • Elkind-Hirsch K.
        • Marrioneaux O.
        • Bhushan M.
        • Vernor D.
        • Bhushan R.
        Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2008; 93: 2670-2678
        • Tzotzas T.
        • Karras S.N.
        • Katsiki N.
        Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome.
        Curr Vasc Pharmacol. 2017; 15: 218-229
        • Baillargeon J.P.
        • Jakubowicz D.J.
        • Iuorno M.J.
        • Jakubowicz S.
        • Nestler J.E.
        Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
        Fertil Steril. 2004; 82: 893-902
        • Du Q.
        • Wang Y.J.
        • Yang S.
        • Wu B.
        • Han P.
        • Zhao Y.Y.
        A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
        Curr Med Res Opin. 2012; 28: 723-730
        • Xu Y.
        • Wu Y.
        • Huang Q.
        Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis.
        Arch Gynecol Obstet. 2017; 296: 661-677
        • Bucher K.G.
        • Wiltz S.A.
        Alternatives to metformin for patients with PCOS.
        Am Fam Physician. 2016; 94: 378-379
        • Du Q.
        • Yang S.
        • Wang Y.J.
        • Wu B.
        • Zhao Y.Y.
        • Fan B.
        Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.
        Adv Ther. 2012; 29: 763-774
        • Glueck C.J.
        • Moreira A.
        • Goldenberg N.
        • Sieve L.
        • Wang P.
        Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
        Hum Reprod. 2003; 18: 1618-1625
        • Graff S.K.
        • Mario F.M.
        • Ziegelmann P.
        • Spritzer P.M.
        Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis.
        Int J Clin Pract. 2016; 70: 450-461
        • Cho L.W.
        • Kilpatrick E.S.
        • Keevil B.G.
        • Coady A.M.
        • Atkin S.L.
        Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
        Clin Endocrinol (Oxf). 2009; 70: 233-237
        • Kumar P.
        • Arora S.
        Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates.
        J Hum Reprod Sci. 2014; 7: 255-261
        • Panidis D.
        • Farmakiotis D.
        • Rousso D.
        • Kourtis A.
        • Katsikis I.
        • Krassas G.
        Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
        Fertil Steril. 2008; 89: 899-906
        • Panidis D.
        • Tziomalos K.
        • Papadakis E.
        • Chatzis P.
        • Kandaraki E.A.
        • Tsourdi E.A.
        • et al.
        The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
        Clin Endocrinol (Oxf). 2014; 80: 432-438
        • Diamanti-Kandarakis E.
        • Katsikis I.
        • Piperi C.
        • Alexandraki K.
        • Panidis D.
        Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
        Clin Endocrinol (Oxf). 2007; 66: 103-109
        • Zhang Y.Y.
        • Hou L.Q.
        • Zhao T.Y.
        Effects of acarbose on polycystic ovary syndrome: a meta-analysis.
        Exp Clin Endocrinol Diabetes. 2014; 122: 373-378
        • Kircher C.
        • Smith K.P.
        Acarbose for polycystic ovary syndrome.
        Ann Pharmacother. 2008; 42: 847-851
        • Hanjalic-Beck A.
        • Gabriel B.
        • Schaefer W.
        • Zahradnik H.P.
        • Schories M.
        • Tempfer C.
        • et al.
        Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.
        Gynecol Endocrinol. 2010; 26: 690-697
        • Penna I.A.
        • Canella P.R.
        • Reis R.M.
        • Silva de Sa M.F.
        • Ferriani R.A.
        Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.
        Hum Reprod. 2005; 20: 2396-2401
        • Robinson M.K.
        Surgical treatment of obesity—weighing the facts.
        N Engl J Med. 2009; 361: 520-521
        • Eid G.M.
        • Cottam D.R.
        • Velcu L.M.
        • Mattar S.G.
        • Korytkowski M.T.
        • Gosman G.
        • et al.
        Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass.
        Surg Obes Relat Dis. 2005; 1: 77-80
        • Schauer P.R.
        • Bhatt D.L.
        • Kirwan J.P.
        • Wolski K.
        • Brethauer S.A.
        • Navaneethan S.D.
        • et al.
        Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes.
        N Engl J Med. 2014; 370: 2002-2013
        • Hutch C.R.
        • Sandoval D.
        The role of GLP-1 in the metabolic success of bariatric surgery.
        Endocrinology. 2017; 158: 4139-4151
        • Pareek M.
        • Schauer P.R.
        • Kaplan L.M.
        • Leiter L.A.
        • Rubino F.
        • Bhatt D.L.
        Metabolic surgery: weight loss, diabetes, and beyond.
        J Am Coll Cardiol. 2018; 71: 670-687
        • Johansson K.
        • Cnattingius S.
        • Naslund I.
        • Roos N.
        • Trolle Lagerros Y.
        • Granath F.
        • et al.
        Outcomes of pregnancy after bariatric surgery.
        N Engl J Med. 2015; 372: 814-824
        • Mechanick J.I.
        • Youdim A.
        • Jones D.B.
        • Garvey W.T.
        • Hurley D.L.
        • McMahon M.M.
        • et al.
        Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery.
        Obesity (Silver Spring). 2013; 21: S1-27
        • Bhandari S.
        • Ganguly I.
        • Bhandari M.
        • Agarwal P.
        • Singh A.
        • Gupta N.
        • et al.
        Effect of sleeve gastrectomy bariatric surgery-induced weight loss on serum AMH levels in reproductive aged women.
        Gynecol Endocrinol. 2016; 32: 799-802
        • Wang K.
        • Jiang Q.
        • Zhi Y.
        • Zhu Z.
        • Zhou Z.
        • Xie Y.
        • et al.
        Contrasting sleeve gastrectomy with lifestyle modification therapy in the treatment of polycystic ovary syndrome.
        J Laparoendosc Adv Surg Tech A. 2015; 25: 493-498
        • Jakobsen G.S.
        • Smastuen M.C.
        • Sandbu R.
        • Nordstrand N.
        • Hofso D.
        • Lindberg M.
        • et al.
        Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities.
        JAMA. 2018; 319: 291-301
        • Cook F.J.
        • Khanna I.
        • Giordano J.
        • Matarese L.
        • Hudson S.
        Long-term bone health after Roux-en-Y gastric bypass: a pilot study.
        Endocr Pract. 2017; 23: 1077-1084
        • Switzer N.J.
        • Marcil G.
        • Prasad S.
        • Debru E.
        • Church N.
        • Mitchell P.
        • et al.
        Long-term hypovitaminosis D and secondary hyperparathyroidism outcomes of the Roux-en-Y gastric bypass: a systematic review.
        Obes Rev. 2017; 18: 560-566
        • Daigle C.R.
        • Brethauer S.A.
        • Tu C.
        • Petrick A.T.
        • Morton J.M.
        • Schauer P.R.
        • et al.
        Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes.
        Surg Obes Relat Dis. 2018; 14: 652-657
        • Axelsson K.F.
        • Werling M.
        • Eliasson B.
        • Szabo E.
        • Naslund I.
        • Wedel H.
        • et al.
        Fracture risk after gastric bypass surgery: a retrospective cohort study.
        J Bone Miner Res. 2018; https://doi.org/10.02/jbmr.3553
        • Wang F.G.
        • Yan W.M.
        • Yan M.
        • Song M.M.
        Outcomes of Mini vs Roux-en-Y gastric bypass: a meta-analysis and systematic review.
        Int J Surg. 2018; 56: 7-14
        • Sudan R.
        • Jain-Spangler K.
        Tailoring bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch.
        J Laparoendosc Adv Surg Tech A. 2018; 28: 956-961
        • Kolotkin R.L.
        • Kim J.
        • Davidson L.E.
        • Crosby R.D.
        • Hunt S.C.
        • Adams T.D.
        12-year trajectory of health-related quality of life in gastric bypass patients versus comparison groups.
        Surg Obes Relat Dis. 2018; 14: 1359-1365
        • Janik M.R.
        • Mustafa R.R.
        • Rogula T.G.
        • Alhaj Saleh A.
        • Abbas M.
        • Khaitan L.
        Safety of laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass in elderly patients - analysis of the MBSAQIP.
        Surg Obes Relat Dis. 2018; 14: 1276-1282
        • Coleman K.J.
        • Huang Y.C.
        • Hendee F.
        • Watson H.L.
        • Casillas R.A.
        • Brookey J.
        Three-year weight outcomes from a bariatric surgery registry in a large integrated healthcare system.
        Surg Obes Relat Dis. 2014; 10: 396-403
        • Garb J.
        • Welch G.
        • Zagarins S.
        • Kuhn J.
        • Romanelli J.
        Bariatric surgery for the treatment of morbid obesity: a meta-analysis of weight loss outcomes for laparoscopic adjustable gastric banding and laparoscopic gastric bypass.
        Obes Surg. 2009; 19: 1447-1455
        • Kjaer M.M.
        • Madsbad S.
        • Hougaard D.M.
        • Cohen A.S.
        • Nilas L.
        The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women.
        Gynecol Endocrinol. 2017; 33: 160-163
        • Zhou J.Q.
        • Zhou L.M.
        • Chen L.J.
        • Han J.D.
        • Wang Q.
        • Fang Z.Y.
        • et al.
        Polycystic ovary syndrome in patients with epilepsy: a study in 102 Chinese women.
        Seizure. 2012; 21: 729-733
        • Zhang L.
        • Li H.
        • Li S.
        • Zou X.
        Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis.
        Eur J Obstet Gynecol Reprod Biol. 2016; 202: 26-31
        • Yazici D.
        • Sezer H.
        Insulin resistance, obesity and lipotoxicity.
        Adv Exp Med Biol. 2017; 960: 277-304
        • Khera R.
        • Murad M.H.
        • Chandar A.K.
        • Dulai P.S.
        • Wang Z.
        • Prokop L.J.
        • et al.
        Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis.
        JAMA. 2016; 315: 2424-2434